Tecan N

Tecan presented its transformation program “Rewired” at the Morgan Stanley Global Healthcare Conference, aiming to boost margins and drive growth. Key strategic elements include partnerships with NVIDIA and Anthropic for AI-powered lab automation, along with portfolio adjustments and cost reductions. Tecan expects a currency-adjusted EBITDA margin of 20% by 2028, sees a recovery in the biopharma segment and weak demand from the academic sector. Operationally, management cited supply issues at Cavro, a partially completed CHF 120 million buyback program, and targeted M&A to strengthen the life-sciences portfolio. » More on de.investing.com

Tecan will participate on 14 September 2026 in the 24th annual Morgan Stanley Healthcare Conference in New York and will be represented in a fireside chat. Participants are CEO Monica Manotas, CFO Camila Japur and Martin Brändle (SVP Corporate Communications & IR); a webcast will be streamed live on the investor overview at www.tecan.com and will be available for 120 days. » More on finanzen.net

Tecan reported H1 2026 revenue of 427.5 million CHF and adjusted EBITDA of 64.5 million CHF (margin 15.1%), but showed weaker reported revenue, a sharply reduced operating cash flow of 17 million CHF and margin pressure. The share fell about 9% to $183.90 as investors reacted particularly to the decline in gross margins and continued transformation spending. Management kept the full-year guidance unchanged and expects low single-digit revenue growth and an adjusted EBITDA margin of 15.5–16.5%, now targeting the top end of the range. » More on de.investing.com

Tecan will explain the financial results for the first half of 2026 on Tuesday, 11 August 2026 at 09:00 CET in an English-language conference call; the press release will be published the same morning at 07:00 CET. The presentation will be available via telephone dial-in or webcast with synchronized slides; dial-in details will be published in advance. The full half-year report 2026 will be available from 11 August in the Investor Relations section of the company website. » More on finanzen.net

At the annual general meeting on 15 April 2026, Tecan (N) approved a dividend of CHF 3.00 per share for 2025, totaling CHF 38.03 million. The dividend yield for 2025 is 2.33% based on the closing price on the AGM date of CHF 141.40; the stock is trading ex-dividend as of today. Over three years the share price is down around 64.98%. Analysts at FactSet expect the dividend to rise to CHF 3.40 by 2029. » More on finanzen.net